Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Now three months past its conjunction with the sun in March, Saturn is currently well separated from the dawn glow. On June 1 ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company specializing in mRNA therapeutics and vaccines, stands at a critical juncture as it navigates a rapidly ...

If you’re a night owl, this is the perfect time of year for you, as stargazing has now become a late-night delight! Catch an ...

Venus continues to be the brilliant “Morning Star” in the East before dawn, albeit dimming just a bit as it moves away from ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Sector Outperform recommendation. As of May 7, 2025, the average one ...

SAN DIEGO, May 12, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

June’s night skies provide excellent opportunities to discover a slice of the evening sky that is largely unsung, unheralded ...

On Wednesday, Scotiabank (TSX: BNS) began coverage on Arcturus Therapeutics (NASDAQ: ARCT), assigning a Sector Outperform rating and setting a price target of $32.00.Currently trading at $11.77 ...

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago. These ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.